Quart Barry D 4

What Happened

• Barry D. Quart, a director of Kiniksa Pharmaceuticals International (KNSA), exercised 6,901 vested options on 2026-04-06 (exercise price $14.33, cost $98,891) and sold the 6,901 shares the same day in an open-market sales program for a weighted average price of $50.00 per share (total proceeds $345,050).
• The exercises and sale were effected under a pre-established 10b5-1 trading plan and the option was fully vested.

Key Details

• Transaction date: April 6, 2026; Form 4 filed April 8, 2026 (appears filed within the normal two-business-day window).
• Exercise: 6,901 shares at $14.33 (total cost $98,891).
• Sale: 6,901 shares at a weighted average price of $50.00 (total proceeds $345,050); sales executed in multiple trades at prices between $50.00 and $50.015.
• Form shows a derivative conversion line (6,901 at $0.00) reflecting the option-to-stock conversion.
• Notable footnotes: transaction done under a 10b5-1 plan (Sep 11, 2025); option fully vested. The filing does not list post-transaction total shares beneficially owned in the provided excerpt.

Context

• This was effectively a cashless exercise: options were exercised and the resulting shares were sold the same day. For retail investors, purchases (insider buys) often carry more signal than routine sales; here the activity reflects monetizing vested options under a trading plan rather than an open-market directional buy.